Furthermore, our results confirm the superior neuroprotective effect of a single dose of hS3 compared to EPO, which is in line with the higher expression patterns of hS3 mRNA observed in human stroke brains and supporting the concept of hS3 as a relevant endogenous neuroprotectant. Here, EPO is linked to stroke disorder.